In a pregnant patient with a Pap smear showing no intra‑epithelial lesion or malignancy (NILM) but positive for high‑risk human papillomavirus type 16, what is the appropriate management?

Management of Pap NILM with HPV-16 Positive in Pregnancy

In a pregnant patient with NILM cytology but positive for HPV-16, colposcopy is recommended, though it is acceptable to defer this evaluation until at least 6 weeks postpartum. 1

Rationale and Risk Stratification

The presence of HPV-16 with NILM cytology represents a clinically significant risk scenario. Research demonstrates that HPV-16 positive/NILM carries a 1-year risk of ≥CIN3 of approximately 14%, which is higher than LSIL alone (7.9%) and similar to hrHPV-positive/LSIL (11.5%) 2. This elevated risk justifies colposcopic evaluation even with normal cytology.

HPV-16 is uniquely concerning because:

• It carries the highest oncogenic potential among all HPV types 3
• HPV-16 positivity is associated with increased risk of persistence and progression compared to other genotypes 3
• The 3-year ≥CIN3 risk for HPV-16/NILM approaches 14-24% depending on subsequent findings 2

Pregnancy-Specific Management Algorithm

Initial Evaluation

1. Colposcopy is preferred but may be deferred until ≥6 weeks postpartum 1
2. Endocervical curettage is absolutely contraindicated in pregnancy 1, 4, 1
3. Colposcopy should ideally be performed by clinicians experienced in pregnancy-related colposcopic changes 1

During Colposcopy

• Biopsy only lesions suspicious for CIN 2,3 or cancer 1, 4
• Biopsy of other lesions is acceptable but not mandatory 1
• The goal is to rule out invasion, not to diagnose or treat preinvasive disease 3

If No CIN 2,3 or Cancer Found

• Postpartum follow-up is recommended 1
• Additional colposcopic and cytologic examinations during pregnancy are unacceptable 1
• Re-evaluation with cytology and colposcopy at ≥6 weeks postpartum 1

If CIN 2,3 is Identified

• Treatment is deferred until after delivery unless invasive cancer is suspected 5, 1, 4
• Surveillance during pregnancy aims only to exclude progression to invasion 3
• Pregnant women with CIN 3 can wait until after delivery for treatment 5

Critical Pitfalls to Avoid

Do not perform endocervical curettage - This is explicitly unacceptable in pregnancy and carries risk of complications 1, 4, 1

Do not treat preinvasive lesions during pregnancy - Unless invasive cancer is identified, all treatment should be deferred to postpartum 5, 1, 4

Do not perform serial colposcopies during pregnancy - If initial colposcopy shows no high-grade disease or cancer, additional examinations during pregnancy are not indicated 1

Do not dismiss HPV-16 positivity despite NILM cytology - The risk is substantial enough to warrant colposcopic evaluation, as cytology can miss significant disease 2

Postpartum Management

At ≥6 weeks postpartum, comprehensive re-evaluation should include:

• Repeat cytology
• Colposcopy with directed biopsies as indicated
• Definitive treatment if CIN 2,3 is confirmed histologically

The postpartum period allows for complete assessment and appropriate treatment without pregnancy-related constraints or risks to the fetus.

Special Considerations

Counseling points for the patient:

• HPV-16 infection in pregnancy is more common than in non-pregnant women 6
• Most cervical lesions do not progress during pregnancy, and 10-70% may regress postpartum 7
• The risk of invasive cancer during pregnancy is very low (approximately 3% of cervical cancers are diagnosed during pregnancy) 7
• Compliance with postpartum follow-up is essential, as this is when definitive diagnosis and treatment occur

The conservative approach during pregnancy balances:

• The need to exclude invasive disease (which requires immediate intervention)
• The low likelihood of rapid progression during the 9-month gestation period
• The risks of intervention during pregnancy, including potential pregnancy complications
• The opportunity for spontaneous regression postpartum